Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
VRTX

VRTX - Vertex Pharmaceuticals Inc Stock Price, Fair Value and News

470.20USD+1.49 (+0.32%)Delayed as of 24 Jun 2024, 10:24 am ET

Market Summary

VRTX
USD470.20+1.49
Delayedas of 24 Jun 2024, 10:24 am
0.32%

VRTX Alerts

  • 6 major insider sales recently.
  • Big jump in Earnings (Y/Y)

VRTX Stock Price

View Fullscreen

VRTX RSI Chart

VRTX Valuation

Market Cap

121.0B

Price/Earnings (Trailing)

30.09

Price/Sales (Trailing)

11.88

EV/EBITDA

22.72

Price/Free Cashflow

32.54

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

46.81%

Return on Equity

21.67%

Return on Assets

16.81%

Free Cashflow Yield

3.07%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

10.2B

Rev. Growth (Yr)

13.3%

Rev. Growth (Qtr)

6.87%

VRTX Earnings

Earnings (TTM)

4.0B

Earnings Growth (Yr)

57.13%

Earnings Growth (Qtr)

13.5%

Breaking Down VRTX Revenue

52 Week Range

335.82472.89
(Low)(High)

Last 7 days

-2.5%

Last 30 days

4.7%

Last 90 days

12.7%

Trailing 12 Months

34.6%

How does VRTX drawdown profile look like?

VRTX Financial Health

Current Ratio

3.5

VRTX Investor Care

Shares Dilution (1Y)

0.19%

Diluted EPS (TTM)

15.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202410.2B000
20239.2B9.5B9.7B9.9B
20227.9B8.4B8.7B8.9B
20216.4B6.7B7.1B7.6B
20204.8B5.4B6.0B6.2B
20193.3B3.5B3.6B4.2B
20182.4B2.6B2.8B3.0B
20172.0B2.1B2.3B2.5B
20161.3B1.6B1.7B1.7B
2015600.5M628.1M759.0M1.0B
20141.0B829.7M787.0M580.4M
20131.4B1.3B1.2B1.2B
20121.8B2.1B1.8B1.5B
2011194.6M277.4M912.8M1.4B
2010100.3M112.9M111.7M143.4M
2009157.1M138.7M120.3M101.9M
2008000175.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Vertex Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
bozic carmen
sold
-1,089,840
478
-2,280
evp and cmo
Jun 12, 2024
atkinson edward morrow iii
sold
-3,483,660
478
-7,288
evp, chief technical ops. off.
Jun 11, 2024
atkinson edward morrow iii
sold (taxes)
-3,288,900
481
-6,824
evp, chief technical ops. off.
Jun 05, 2024
sachdev amit
gifted
-
-
-4,600
evp chief patient & ext af off
Jun 03, 2024
tatsis ourania
sold
-1,000,500
460
-2,175
evp, chief reg. & quality off.
Jun 03, 2024
wagner charles f jr
sold
-1,495,000
460
-3,250
evp & chief financial officer
May 31, 2024
tatsis ourania
sold
-1,001,250
445
-2,250
evp, chief reg. & quality off.
May 30, 2024
tatsis ourania
sold
-1,031,910
439
-2,350
evp, chief reg. & quality off.
May 29, 2024
bozic carmen
sold
-1,015,880
445
-2,280
evp and cmo
May 28, 2024
wagner charles f jr
sold
-1,478,070
454
-3,250
evp & chief financial officer

1–10 of 50

Which funds bought or sold VRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 21, 2024
Abich Financial Wealth Management LLC
added
16.67
1,454
8,778
0.01%
Jun 21, 2024
Cape Investment Advisory, Inc.
reduced
-87.89
-91,206
12,958
0.01%
Jun 20, 2024
HM PAYSON & CO
reduced
-0.3
19,977
842,709
0.02%
Jun 13, 2024
NBW CAPITAL LLC
added
5.2
638,692
8,545,380
1.75%
Jun 11, 2024
Jackson Wealth Management, LLC
added
1.31
58,000
1,486,000
0.19%
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
1.62
-4,389
221,841
0.02%
Jun 07, 2024
Railway Pension Investments Ltd
added
0.91
1,474,860
41,675,600
0.41%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-2.55
-1,711,000
204,090,000
0.38%
May 31, 2024
Granite Group Advisors, LLC
unchanged
-
4,028
475,695
0.32%
May 30, 2024
EULAV Asset Management
reduced
-1.3
218,003
15,842,600
0.44%

1–10 of 48

Are Funds Buying or Selling VRTX?

Are funds buying VRTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VRTX
No. of Funds

Unveiling Vertex Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
capital world investors
10.0%
25,902,938
SC 13G/A
Feb 13, 2024
vanguard group inc
8.65%
22,281,729
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital world investors
8.6%
22,080,207
SC 13G/A
Jan 25, 2024
blackrock inc.
8.5%
21,881,203
SC 13G
Feb 13, 2023
capital world investors
5.0%
12,939,319
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G
Feb 09, 2023
vanguard group inc
8.39%
21,546,903
SC 13G/A
Jan 24, 2023
blackrock inc.
9.4%
24,241,437
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
2.1%
5,421,291
SC 13G/A

Recent SEC filings of Vertex Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 07, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 03, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to Vertex Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
21.0B
2.0B
9.73% -16.82%
-63.12
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.43
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Vertex Pharmaceuticals Inc News

Latest updates
Yahoo Finance17 minutes ago

Vertex Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue6.9%2,6912,5182,4842,4932,3752,3032,3342,1962,0982,0731,9841,7931,7241,6281,5381,5241,5151,413950941858
Costs and Expenses1.4%1,5511,5291,4451,4671,5961,2691,2081,0901,0571,1959301,831837882866806795862850671582
  S&GA Expenses-7.2%343369264263241267247215215255198195192212185192182195160157147
  R&D Expenses---------6036944941,407456467493421449480556379339
EBITDA Margin5.6%0.48*0.46*0.46*0.46*0.46*0.48*0.47*0.48*0.37*0.37*0.40*0.37*---------
Interest Expenses1.9%-10.40-10.60-10.90-11.20-11.40-11.60-13.70-14.60-14.90-15.10-15.20-15.50-15.7016.00-13.86-13.87-14.1414.0015.0015.0015.00
Income Taxes0.4%180179144246192258246214193101231-11116828478.00-12.5055.0094.0013.0060.0052.00
Earnings Before Taxes11.5%1,2791,1481,1791,1628921,0771,1761,0249558711,083-44.2082188974682565867771.00327320
EBT Margin5.5%0.47*0.44*0.45*0.45*0.45*0.47*0.46*0.47*0.36*0.36*0.39*0.36*---------
Net Income13.5%1,1009691,03591670081993181176277085267.0065360466783760358358.00267269
Net Income Margin7.6%0.39*0.37*0.36*0.35*0.35*0.37*0.38*0.38*0.31*0.31*0.31*0.30*---------
Free Cashflow601.5%1,2381771,2281,0758581,0459011,087893933875-249---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets5.2%23,91722,73021,72620,34918,97418,15116,70615,58214,25613,43312,61912,22212,11511,75211,30210,2168,8938,3187,5157,0336,543
  Current Assets-6.0%13,28914,14414,69613,87312,96613,23512,27111,50410,3619,5618,8538,4588,5398,1337,4586,6945,4464,8234,7774,7114,183
    Cash Equivalents-11.7%9,15810,36911,11010,1519,29010,5049,1728,7027,6006,7956,2766,0646,3045,9885,3584,8313,5933,1093,3983,2952,894
  Inventory10.1%813739689604535461388368339353333322299281245219187168162143137
  Net PPE---------------92172873674517.00731743
  Goodwill0%1,0881,0881,0881,0881,0881,08886.001,0021,0021,0021,0021,0021,0021,0001,0021,0021,0021,00044850.0050.00
Liabilities4.3%5,3715,1505,2134,8794,5424,2383,6773,6493,3493,3333,0883,0253,1353,0653,1682,6972,4322,2332,2611,9641,820
  Current Liabilities7.0%3,7963,5473,5993,3523,0262,7422,6092,5562,1802,1421,9141,8361,9441,8782,0041,7991,5391,3351,3891,2591,106
Shareholder's Equity5.5%18,54717,58016,51315,47014,43213,91313,03011,93410,90710,1009,5319,1968,9808,6878,1337,5196,4626,0855,2535,0704,723
  Retained Earnings10.8%11,24210,1429,1748,1387,2236,5235,7044,7733,9633,2012,4311,5791,512859254-412-1,250-1,852-2,436-2,493-2,761
  Additional Paid-In Capital-2.2%7,2857,4507,3407,3697,2207,3877,2267,1006,9306,8817,0867,6407,4997,8947,9177,9447,6967,9387,6687,5647,476
Shares Outstanding0.2%258258258258257257256256255258258259---------
Float----90,700---71,800---51,600---74,800---46,700-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations456.9%1,3072351,2681,1349001,0789561,140956995927-1999214929081,039816446335464325
  Share Based Compensation-8.0%19220913111912211213611413011910310511597.0010011711692.0085.0090.0094.00
Cashflow From Investing-141.0%-2,136-886-117-303-1,833176-384-61.50-51.00-134-52.90-79.70-74.30244-24772.0032.00-896-249-50.19-39.14
Cashflow From Financing-198.4%-357-119-16517.00-29440.00-60.2048.00-95.40-336-65634.00-518-125-140120-35916120.00-13.01-41.99
  Buy Backs-11.3%13114812326.00133----363642-425131108-30032.0012.0052.0094.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VRTX Income Statement

2024-03-31
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Product revenues, net$ 2,690.6$ 2,374.8
Costs and expenses:  
Cost of sales342.6266.9
Research and development expenses789.1742.6
Acquired in-process research and development expenses76.8347.1
Selling, general and administrative expenses342.7241.1
Change in fair value of contingent consideration(0.1)(1.9)
Total costs and expenses1,551.11,595.8
Income from operations1,139.5779.0
Interest income181.2122.6
Interest expense(10.4)(11.4)
Other (expense) income, net(31.2)1.3
Income before provision for income taxes1,279.1891.5
Provision for income taxes179.5191.7
Net income$ 1,099.6$ 699.8
Net income per common share:  
Basic (in dollars per share)$ 4.26$ 2.72
Diluted (in dollars per share)$ 4.21$ 2.69
Shares used in per share calculations:  
Basic (in shares)258.2257.4
Diluted (in shares)261.1260.3

VRTX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 9,158.0$ 10,369.1
Marketable securities1,013.3849.2
Accounts receivable, net1,793.21,563.4
Inventories813.1738.8
Prepaid expenses and other current assets511.1623.7
Total current assets13,288.714,144.2
Property and equipment, net1,172.81,159.3
Goodwill1,088.01,088.0
Other intangible assets, net834.9839.9
Deferred tax assets1,963.01,812.1
Operating lease assets312.9293.6
Long-term marketable securities4,381.42,497.8
Other assets875.7895.3
Total assets23,917.422,730.2
Current liabilities:  
Accounts payable351.4364.9
Accrued expenses2,795.92,655.3
Other current liabilities648.6527.2
Total current liabilities3,795.93,547.4
Long-term finance lease liabilities361.5376.1
Long-term operating lease liabilities359.8348.6
Other long-term liabilities853.6877.7
Total liabilities5,370.85,149.8
Commitments and contingencies0.00.0
Shareholders’ equity:  
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding0.00.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively2.62.6
Additional paid-in capital7,284.77,449.7
Accumulated other comprehensive income (loss)17.3(14.3)
Retained earnings11,242.010,142.4
Total shareholders’ equity18,546.617,580.4
Total liabilities and shareholders’ equity$ 23,917.4$ 22,730.2
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEvrtx.com
 INDUSTRYBiotechnology
 EMPLOYEES4800

Vertex Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Vertex Pharmaceuticals Inc? What does VRTX stand for in stocks?

VRTX is the stock ticker symbol of Vertex Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vertex Pharmaceuticals Inc (VRTX)?

As of Fri Jun 21 2024, market cap of Vertex Pharmaceuticals Inc is 120.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers. The fair value of Vertex Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vertex Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vertex Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRTX is over valued or under valued. Whether Vertex Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vertex Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRTX.

What is Vertex Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, VRTX's PE ratio (Price to Earnings) is 30.09 and Price to Sales (PS) ratio is 11.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vertex Pharmaceuticals Inc's stock?

In the past 10 years, Vertex Pharmaceuticals Inc has provided 0.175 (multiply by 100 for percentage) rate of return.